Increased Serum Brain-derived Neurotrophic Factor, Nerve Growth Factor, Glial-derived Neurotrophic Factor and Galanin Levels in Children with Attention Deficit Hyperactivity Disorder, and the Effect of 10 Weeks Methylphenidate Treatment

키워드

참고문헌 (66)

1. Millichap JG, "Etiologic classification of attention-deficit", hyperactivity disorder, 2008, pp.121, e358~e365
2. Tsai SJ, "Role of neurotrophic factors in attention deficit hyperactivity disorder", Cytokine Growth Factor Rev, 34, pp.35~41 (2017)
3. Reichardt LF, "Neurotrophin-regulated signalling pathways", Philos Trans R Soc Lond B Biol Sci, 361, pp.1545~1564 (2006)
4. Goodman LJ, "Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons", Mol Cell Neurosci, 7, pp.222~238 (1996)
5. Galvez-Contreras AY, "Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders", Cytokine Growth Factor Rev, 32, pp.85~96 (2016)
6. Lee BH, "Decreased plasma BDNF level in depressive patients", J Affect Disord, 101, pp.239~244 (2007)
7. Fontenelle LF, "Neurotrophic factors in obsessive-compulsive disorder", Psychiatry Res, 199, pp.195~200 (2012)
8. Şimşek Ş, "Cortisol and brain-derived neurotrophic factor levels prior to treatment in children with obsessive-compulsive disorder", J Clin Psychiatry, 77, pp.e855~e859 (2016)
9. Shim SH, "Increased levels of plasma brain-derived neurotrophic factor(BDNF)in children with attention deficit-hyperactivity disorder(ADHD)", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1824~1828 (2008)
10. Li H, "Sex-specific association of brain-derived neurotrophic factor(BDNF)Val66Met polymorphism and plasma BDNF with attention-deficit", hyperactivity disorder in a drug-naïve Han Chinese sample, 2014, pp.217, 191~197
11. Sargin E, "Evaluation of serum brain-derived neurotrophic factor levels in children with attention deficit hyperactivity disorder : preliminary data", Arch Neuropsychiatry, 49, pp.96~101 (2012)
12. Sahin S, "Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder", Int J Psychiatry Clin Pract, 18, pp.280~287 (2014)
13. Scassellati C, "Serum brain-derived neurotrophic factor(BDNF)levels in attention deficit-hyperactivity disorder(ADHD)", Eur Child Adolesc Psychiatry, 23, pp.173~177 (2014)
14. Şimşek Ş, "Evaluation of the relationship between brain-derived neurotropic factor levels and the stroop interference effect in children with attention-deficit hyperactivity disorder", Noro Psikiyatr Ars, 53, pp.348~352 (2016)
15. Bilgiç A, "Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit", hyperactivity disorder, 2017, pp.26, 355~363
16. Akay AP, "Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit", hyperactivity disorder treated with methylphenidate : an 8-week, observational pretest-posttest study, 2018, pp.27, 127~135
17. Wang LJ, "Peripheral brain-derived neurotrophic factor and contactin-1levels in patients with attention-deficit", hyperactivity disorder, 2019, pp.8, 1366~
18. Yurteri N, "Altered serum levels of vascular endothelial growth factor and glial-derived neurotrophic factor but not fibroblast growth factor-2 in treatment-naive children with attention deficit", hyperactivity disorder, 2019, pp.73, 302~307
19. Saadat F, "Brain-derived neurotrophic factor as a biomarker in children with attention deficit-hyperactivity disorder", J Krishna Inst Med Sci Univ, 4, pp.10~17 (2015)
20. Cubero-Millán I, "BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology", Psychopharmacology(Berl), 234, pp.267~279 (2017)
21. Chang JP, "Cortisol, inflammatory biomarkers and neurotrophins in children and adolescents with attention deficit hyperactivity disorder(ADHD)in Taiwan", Brain Behav Immun, 88, pp.105~113 (2020)
22. Ciafrè S, "Nerve growth factor in brain diseases", Biomed Rev, 29, pp.1~16 (2018)
23. Diniz BS, "Reduced serum nerve growth factor in patients with late-life depression", Am J Geriatr Psychiatry, 21, pp.493~496 (2013)
24. Xiong P, "The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia", Psychiatry Res, 189, pp.72~76 (2011)
25. Guney E, "Serum nerve growth factor(NGF)levels in children with attention deficit", hyperactivity disorder(ADHD), 2014, pp.560, 107~111
26. Allen SJ, "GDNF, NGF and BDNF as therapeutic options for neurodegeneration", Pharmacol Ther, 138, pp.155~175 (2013)
27. Gerlai R, "Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation", Eur J Neurosci, 14, pp.1153~1163 (2001)
28. Pedrotti Moreira F, "Serum GDNF levels and anxiety disorders in a population-based study of young adults", Clin Chim Acta, 485, pp.21~25 (2018)
29. Skibinska M, "Glial Cell Line-Derived Neurotrophic Factor(GDNF)serum level in women with schizophrenia and depression, correlation with clinical and metabolic parameters", Psychiatry Res, 256, pp.396~402 (2017)
30. Shim SH, "Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder", Nord J Psychiatry, 69, pp.546~551 (2015)
31. Mills EG, "Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour", Nat Rev Endocrinol, 17, pp.97~113 (2021)
32. Wang YJ, "Plasma galanin is a biomarker for severity of major depressive disorder", Int J Psychiatry Med, 48, pp.109~119 (2014)
33. Saad K, "Serum galanin in children with autism spectrum disorder", Child Psychiatry Hum Dev, 53, pp.300~306 (2022)
34. Murck H, "Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG", Psychoneuroendocrinology, 29, pp.1205~1211 (2004)
35. Heberlein A, "Decreased galanin serum levels are associated with alcohol-craving during withdrawal", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.568~572 (2011)
36. Kaufman J, "Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version(K-SADS-PL) : initial reliability and validity data", J Am Acad Child Adolesc Psychiatry, 36, pp.980~988 (1997)
37. Gökler B, "Okul çağı çocukları için duygulanım bozukluklarıve şizofreni görüşme çizelgesi-şimdi ve yaşam boyu şekli-(ÇDŞG-ŞY-T)", Çocuk ve Gençlik Ruh Sağlığı Dergisi, 11, pp.109~116 (2004)
38. Conners CK, "The revised Conners’ Parent Rating Scale(CPRS-R) : factor structure, reliability, and criterion validity", J Abnorm Child Psychol, 26, pp.257~268 (1998)
39. Kaner S, "Conners ebeveyn değerlendirme ölçeği yenilenmiş uzun formunun türkçe geçerlilik ve güvenirlik çalışması", XVI. Ulusal Çocuk ve Ergen Psikiyatrisi Kongre Özet Kitabı, pp.69~ (2006)
40. Conners CK, "Revision and restandardization of the Conners Teacher Rating Scale(CTRS-R) : factor structure, reliability, and criterion validity", J Abnorm Child Psychol, 26, pp.279~291 (1998)
41. Kaner S, "The validity and reliability study of the Turkish version of Conners’ Teacher rating scale revisited(CTRS-R)", Türk Psikiyatri Dergisi, 17, pp.227~ (2006)
42. Hyman C, "BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra", Nature, 350, pp.230~232 (1991)
43. Hoffer BJ, "Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo", Neurosci Lett, 182, pp.107~111 (1994)
44. Aloe L, "Nerve growth factor : from the early discoveries to the potential clinical use", J Transl Med, 10, pp.239~ (2012)
45. Liu DY, "The physiology of BDNF and its relationship with ADHD", Mol Neurobiol, 52, pp.1467~1476 (2015)
46. Caraci F, "Metabotropic glutamate receptors in neurodegeneration", neuroprotection : still a hot topic?, 2012, pp.61, 559~565
47. MacMaster FP, "Proton spectroscopy in medication-free pediatric attention-deficit", hyperactivity disorder, 2003, pp.53, 184~187
48. Vellucci SV, "Down-regulation of BDNF mRNA, with no effect on trkB or glucocorticoid receptor m RNAs, in the porcine hippocampus after acute dexamethasone treatment", Res Vet Sci, 70, pp.157~162 (2001)
49. Spoletini M, "Trophic and neurotrophic factors in human pituitary adenomas(Review)", Int J Oncol, 51, pp.1014~1024 (2017)
50. Scassellati C, "Biomarkers and attention-deficit", hyperactivity disorder : a systematic review and meta-analyses, 2012, pp.51, 1003~1019
51. Linnarsson S, "Learning deficit in BDNF mutant mice", Eur J Neurosci, 9, pp.2581~2587 (1997)
52. Leo D, "Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats", J Neurosci, 38, pp.1959~1972 (2018)
53. Syed Z, "An investigation of the neurotrophic factor genes GDNF, NGF, and NT3 in susceptibility to ADHD", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.375~378 (2007)
54. Schimmelmann BG, "No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene(BDNF)in ADHD", J Neural Transm(Vienna), 114, pp.523~526 (2007)
55. Onder Ozturk, "Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism Is a Risk Factor for Attention-Deficit Hyperactivity Disorder in a Turkish Sample", PSYCHIATRY INVESTIGATION, 13(5), pp.518~525 (2016), 대한신경정신의학회[DOI]
56. Zhang J, "Peripheral brain-derived neurotrophic factor in attention-deficit", hyperactivity disorder : a comprehensive systematic review and meta-analysis, 2018, pp.227, 298~304
57. Elfving B, "Detection of brain-derived neurotrophic factor(BDNF)in rat blood and brain preparations using ELISA : pitfalls and solutions", J Neurosci Methods, 187, pp.73~77 (2010)
58. Counts SE, "Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons", J Neurochem, 83, pp.442~451 (2002)
59. Ericson E, "Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission", Brain Res, 822, pp.200~209 (1999)
60. Rada P, "Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens : a possible mechanism for hypothalamic initiation of feeding behavior", Brain Res, 798, pp.1~6 (1998)
61. Medel-Matus JS, "Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy", Exp Neurol, 289, pp.64~72 (2017)
62. Amiri A, "Changes in plasma brain-derived neurotrophic factor(BDNF)levels induced by methylphenidate in children with attention deficit-hyperactivity disorder(ADHD)", Prog Neuropsychopharmacol Biol Psychiatry, 47, pp.20~24 (2013)
63. Schmitz F, "Methylphenidate causes behavioral impairments and neuron and astrocyte loss in the hippocampus of juvenile rats", Mol Neurobiol, 54, pp.4201~4216 (2017)
64. Oakes HV, "Neurogenesis within the hippocampus after chronic methylphenidate exposure", J Neural Transm(Vienna), 126, pp.201~209 (2019)
65. Sadasivan S, "Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice", PLoS One, 7, pp.e33693~ (2012)
66. Ludolph AG, "Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro", J Neural Transm(Vienna), 113, pp.1927~1934 (2006)

관련 논문AI추천